Anthropic is building a physical biology laboratory in the San Francisco area to enable its Claude AI model to guide robotic equipment through drug development experiments. According to a report by Reuters, the initiative aims to move AI-driven life sciences beyond software simulations into physical experimentation with minimal human involvement. Human oversight will remain in place to monitor safety protocols.

To support the lab initiative, Anthropic has released two dedicated tools: Claude Science, an AI workspace tailored for researchers, and the Model Hardware Standard, designed to control lab machinery. The enterprise push builds on Anthropic’s acquisition of startup Coefficient Bio for approximately $400 million earlier this year, alongside adding Novartis CEO Vas Narasimhan to its board of directors.

The effort will focus on designing complex, multi-target antibodies for diseases long considered untreatable. To maintain relationships with commercial partners, Anthropic does not currently plan to conduct its own clinical trials, choosing instead to focus on providing the underlying technological layer for pharmaceutical development.

Why it matters

  • Anthropic is expanding beyond pure software into physical execution infrastructure, setting a precedent for AI-driven physical automation.

  • Standardization efforts like the Model Hardware Standard present opportunities for hardware builders to integrate with AI orchestration layers.

  • Life science startups can leverage automated physical experimentation to accelerate early-stage target discovery and antibody design.

Source: the-decoder.com